Top Stories
Merck Reports Shortage of the Adult Formulation of its HBV Vaccine
Jan. 13 – Beginning in January 2009, Merck expects to experience a supply interruption in the U.S. for the adult formulation of their HBV vaccine, Recombivax HB, but does not anticipate the pediatric formulation will be affected. Read Full Article.
Drug-Induced Liver Injury in the U.S.
Jan. 13 – Research provides an interesting snapshot of clinically significant drug-induced liver injury, with the most commonly implicated single agent being amoxicillin/clavulanate. Read Full Article.
Minimal Hepatic Encephalopathy with Cognitive Impairment Common in Non-Alcoholic Cirrhosis..like HBV and HCV
Jan. 13 – Recent reports reveal that patients with minimal hepatic encephalopathy, a significant complication of cirrhosis, have an increased occurrence of traffic violations and vehicle-related accidents due to cognitive impairments. Read Full Article.
HBF Happenings
Final Statement Available for NIH Consensus Conference on the Management of Hepatitis B
In October 2008, the NIH brought together an independent panel to examine evidence on the management of hepatitis B and identify future research needs. Learn more.
Turn Online Searches & Shopping into Donations for HBF at www.hepb.org/Goodsearch
A Yahoo-powered search engine will donate a penny per search (and a percentage of each sale) to the Hepatitis B Foundation. With 1,000 friends conducting 2 searches a day, our “Click for a Cure” campaign would raise $7,300 (10,000 friends would raise $73,000)! Visit www.hepb.org/GoodSearch to sign up today.
Hepatitis B Foundation Testifies at IOM Public Meeting
At its first public meeting held on Dec. 4 in Washington, D.C., the Institute of Medicine Committee heard presentations from Drs. John Ward, Dale Hu and Cindy Weinbaum from CDC; Martha Saly and Chris Taylor from NVHR; and community presentations by Lorren Sandt from the Hepatitis C Caring Ambassadors and Joan Block from the Hepatitis B Foundation. The IOM is preparing a report on the prevention and control of viral hepatitis in the U.S., slated for publication in 2010, which will impact public policy and federal funding. Learn More.
| 
